PRAX Stock Up 20% after 7-Day Win Streak
Praxis Precision Medicines (PRAX) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 20% return. The company has gained about $213 Mil in value over the last 7 days, with its current market capitalization at about $1.1 Bil. The stock remains 34.3% below its value at the end of 2024. This compares with year-to-date returns of 6.4% for the S&P 500.
Comparing PRAX Stock Returns With The S&P 500
The following table summarizes the return for PRAX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | PRAX | S&P 500 |
|---|---|---|
| 1D | 0.5% | -0.3% |
| 7D (Current Streak) | 20.2% | 0.9% |
| 1M (21D) | 13.5% | 4.2% |
| 3M (63D) | 76.7% | 25.6% |
| YTD 2025 | -34.3% | 6.4% |
| 2024 | 245.4% | 23.3% |
| 2023 | -37.6% | 24.2% |
| 2022 | -87.9% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 42 S&P constituents with 3 days or more of consecutive gains and 50 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 24 |
| 4D | 15 | 15 |
| 5D | 0 | 4 |
| 6D | 2 | 4 |
| 7D or more | 2 | 3 |
| Total >=3 D | 42 | 50 |
Key Financials for Praxis Precision Medicines (PRAX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $2.4 Mil | $8.6 Mil |
| Operating Income | $-126.4 Mil | $-200.2 Mil |
| Net Income | $-123.3 Mil | $-182.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $7.5 Mil | – |
| Operating Income | $-64.0 Mil | $-74.7 Mil |
| Net Income | $-58.7 Mil | $-69.3 Mil |
While PRAX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.